1) Nicholls MG, Richards AM, Yandle TG : The renin-angiotensin system. In : Manual of Hypertension, eds by Giuseppe Mancia, Julius Stevo, John Chalmers et al, Churchill Livingstone, London, 2002, pp.77-95
2) Simpson SA, Tait JF, Wettstein A et al : Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia 9 : 333-335, 1953
3) Conn JW : Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955
4) Ondetti MA, Rubin B, Cushman DW : Design of specific inhibitors of angiotensin-converting enzyme : new class of orally active antihypertensive agents. Science 196 : 441-444, 1977
5) Weinstock J, Keenan RM, Samanen J et al : 1- (carboxybenzyl) imidazole-5-acrylic acids : potent and selective angiotensin II receptor antagonists. J Med Chem 34 : 1514-1517, 1991
6) Kagawa CM, Cella JA, van Arman CG : Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126 : 1015-1016, 1957
7) de Gasparo M, Joss U, Ramjoue HP et al : Three new epoxy-spirolactone derivatives : characterization in vivo and in vitro. J Pharmacol Exp Ther 240 : 650-656, 1987
8) Paul M, Poyan Mehr A, Kreutz R : Physiology of local renin-angiotensin systems. Physiol Rev 86 : 747-803, 2006
9) 岩井將, 堀内正嗣 : レニン・アンジオテンシン系の病態生理 : 脳・認知機能. THE ARB-Angiotensin II Receptor Blocker, 堀内正嗣編, メディカルレビュー社, 東京, 2006, pp.149-155
10) Falkenstein E, Christ M, Feuring M et al : Specific nongenomic actions of aldosterone. Kidney Int 57 : 1390-1394, 2000
11) Harada E, Yoshimura M, Yasue H et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001
12) Ullian ME, Schelling JR, Linas SL : Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 20 : 67-73, 1992
13) 猿田享男 : アルドステロンの新しい作用. 成人病と生活習慣病 38 : 1331-1336, 2008
14) Pitt B, Zannad F, Remm W et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
15) Pitt B, Remme W, Zannad F et al : Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003
16) Stier CT Jr : Eplerenone : a selective aldosterone blocker. Cardiovasc Drug Rev 21 : 169-184, 2003
17) Saruta T, Kageyama S, Ogihara T et al : Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension : a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens (Greenwich) 6 : 175-183, 2004
18) Staessen J, Lijnen P, Fagard R et al : Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 : 457-465, 1981
19) Sato A, Saruta T : Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 (9 Pt 1) : 781-788, 2003
20) Sato A, Hayashi K, Naruse M et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003